M. García

T. Maudelonde, H. Rochefort, M. García, 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.

P. Bunn, W. Franklin, R. Ozols, 2000, Seminars in oncology.

The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells

F. Moreau-Gaudry, E. Lippert, M. García, 2009, Leukemia.

Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry.

B. Pau, M. García, J. Domergue, 1986, Cancer research.

Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines.

M. Sheikh, H. Rochefort, M. García, 1995, Oncogene.

Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

H. Rochefort, M. García, V. Cavaillès, 1988, Nucleic acids research.

Immunodetection of estrogen receptor and 52,000-dalton protein in fine needle aspirates of breast cancer tumors.

H. Rochefort, M. García, J. Domergue, 1987, Journal of the National Cancer Institute.

Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal.

H. Rochefort, M. García, E. Liaudet, 1994, Oncogene.

Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11.

M. Mattei, P. Ferrara, H. Rochefort, 1988, Molecular endocrinology.

Alterations and role of human cathepsin D in cancer metastasis.

H. Rochefort, M. García, E. Liaudet, 1996, Enzyme & protein.

Endocytosis of pro-cathepsin D into breast cancer cells is mostly independent of mannose-6-phosphate receptors.

V. Laurent-Matha, H. Rochefort, A. Lucas, 1998, Journal of cell science.

Estrogen-induced mitogens in breast cancer and their prognostic value.

H. Rochefort, M. García, G. Freiss, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The 52K cathepsin-D of breast cancer: structure, regulation, function and clinical value.

H. Rochefort, M. García, G. Freiss, 1988, Cancer treatment and research.

Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors.

H. Rochefort, M. García, H Rochefort, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Inhibition of cathepsin D by tripeptides containing statine analogs.

D. Scherman, J. Herscovici, K. Antonakis, 1999, Biochemical pharmacology.

Purification and first characterization of the secreted and cellular 52-kDa proteins regulated by estrogens in human-breast cancer cells.

P. Ferrara, H. Rochefort, M. García, 1986, European journal of biochemistry.

The 52K Estrogen‐Regulated Protein Secreted by Breast Cancer Cells and Its Clinical Potential a

H. Rochefort, M. García, F. Vignon, 1986, Annals of the New York Academy of Sciences.

Pregnancy-dependent to ovarian-independent progression in mammary tumors delineated in primary culture: changes in signal transduction, growth factor regulation, and matrix interaction.

M. García, S. Nandi, W. Imagawa, 1992, Cancer research.

The estrogenic and antiestrogenic activities of androgens in female target tissues.

H. Rochefort, M. García, 1983, Pharmacology & therapeutics.

Estrogen-induced proteins in human breast cancer cells.

H. Rochefort, M. García, F. Vignon, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

5-Bromodeoxyuridine specifically inhibits the synthesis of estrogen-induced proteins in MCF7 cells.

H. Rochefort, M. García, B. Westley, 1981, European journal of biochemistry.

Structure, function, regulation and clinical significance of the 52K pro-cathepsin D secreted by breast cancer cells.

T. Maudelonde, H. Rochefort, M. García, 1988, Biochimie.

Evidence and characterization of the binding of two 3H-labeled androgens to the estrogen receptor.

H. Rochefort, M. García, H Rochefort, 1979, Endocrinology.

Carcinoembryonic antigen has a different molecular weight in normal colon and in cancer cells due to N-glycosylation differences.

M. García, H. Reggio, C. Bastid, 1991, Cancer research.

How to target estrogen receptor-negative breast cancer?

H. Rochefort, N. Platet, M. García, 2003, Endocrine-related cancer.

Chordin is underexpressed in ovarian tumors and reduces tumor cell motility

D. Katsaros, P. Pujol, C. Theillet, 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer.

T. Maudelonde, I. Touitou, H. Rochefort, 1989, Journal of steroid biochemistry.

Absence of correlation between antiestrogenic activity and binding affinity for the estrogen receptor.

H. Rochefort, M. García, J. Borgna, 1979, Biochemical and biophysical research communications.

Mechanism of action of antiestrogens and androgens on the estrogen receptor.

H. Rochefort, M. García, F. Capony, 1979, Journal of steroid biochemistry.

Imaging , Diagnosis , Prognosis Prognostic Impact of D TAp 73 Isoform Levels and Their Target Genes in Colon Cancer Patients

M. García, Javier Silva, M. Herrera, 2011 .

Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells.

H. Rochefort, M. García, G. Freiss, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.

I. Christensen, B. Rasmussen, C. Rose, 1989, Cancer research.

Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview.

H. Rochefort, M. García, P. Roger, 2000, Clinica chimica acta; international journal of clinical chemistry.

Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency.

P. Pujol, H. Rochefort, M. García, 1990, Oncogene.

Immunohistochemical detection of the estrogen-regulated 52,000 mol wt protein in primary breast cancers but not in normal breast and uterus.

B. Pau, H. Rochefort, M. García, 1984, The Journal of clinical endocrinology and metabolism.

Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells

M. Maynadier, Marcel Garcia, M. García, 2010, Oncogene.

Androgen effects mediated by estrogen receptor in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors.

H. Rochefort, M. García, 1978, Cancer research.

Effect of antibodies to estrogen receptor on the binding of 3H-labeled antiestrogens and androstanediol in the uterus.

G. Greene, H. Rochefort, M. García, 1982, Endocrinology.

Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters.

T. Maudelonde, B. Pau, H. Rochefort, 1988, Cancer research.

Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor.

T. McCaffrey, A. Haimovitz-Friedman, M. García, 1993, Journal of cellular physiology.

Expression of metalloproteases and their inhibitors in different histological types of breast cancer

M. García, A. Andicoechea, F. Vizoso, 2010, Journal of Cancer Research and Clinical Oncology.

The 52 K protein: an estrogen regulated marker of cell proliferation in human mammary cells.

H. Rochefort, M. García, F. Vignon, 1986, Progress in clinical and biological research.

Effect of Estradiol on Nonmalignant Human Mammary Cells in Primary Culture a

H. Rochefort, M. García, F. Vignon, 1984, Cancer research.

Autocrine stimulation by estradiol-regulated growth factors of rat hormone-responsive mammary cancer: interaction with the polyamine pathway.

H. Rochefort, M. García, L. Demers, 1986, Cancer research.

Antibodies to the estrogen induced 52 K protein released by human breast cancer cells.

H. Rochefort, M. García, F. Capony, 1982, Biochemical and biophysical research communications.

Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness.

M. García, G. Contesso, H. Duplay, 1987, Journal of steroid biochemistry.

Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms.

D. Chalbos, H. Rochefort, S. Cunat, 2000, Molecular endocrinology.

The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships.

S. Andò, A. Russo, S. Cascio, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of tunicamycin and endoglycosidase H and F on the estrogen regulated 52000-Mr protein secreted by breast cancer cells.

I. Touitou, H. Rochefort, M. García, 1985, Biochimie.

Cathepsin D in breast cancer: from molecular and cellular biology to clinical applications.

H. Rochefort, M. García, F. Capony, 1990, Cancer cells.